Aviva
TBPH icon

Aviva’s Theravance Biopharma TBPH Stock Holding History

Aviva’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Sell
26,359
-3,133
-11% -$51.9K ﹤0.01% 759
2026
Q1 		$479K Buy
29,492
+2,682
+10% +$47.4K ﹤0.01% 698
2025
Q4 		$502K Buy
+26,810
New +$445K ﹤0.01% 751

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Aviva's TBPH Position: Q2 2026 in Review

Aviva reduced its Theravance Biopharma (TBPH) stake by 11% in Q2 2026, selling an estimated $51.9K and leaving 26,359 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Aviva first reported a position in TBPH in Q4 2025 and has held it in 3 quarters since. The position peaked at $502K in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Aviva held 26,359 shares of Theravance Biopharma worth $448K as of Q2 2026.
  • Aviva sold 3,133 Theravance Biopharma shares in Q2 2026, an estimated $51.9K.
  • Theravance Biopharma made up ﹤0.01% of Aviva's portfolio in Q2 2026, its #759 holding.
  • Aviva first reported a position in Theravance Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Aviva's Theravance Biopharma position peaked at $502K in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.